Cargando…
Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy
BACKGROUND: Nintedanib is an inhibitor of receptor tyrosine kinases, including vascular endothelial growth factor receptor, but its effects on pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF) patients with chronic hypoxia were unclear. METHODS: This study included a nintedanib pros...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704493/ https://www.ncbi.nlm.nih.gov/pubmed/31438928 http://dx.doi.org/10.1186/s12890-019-0918-3 |
_version_ | 1783445511270825984 |
---|---|
author | Tahara, Masahiro Oda, Keishi Yamasaki, Kei Kawaguchi, Takako Sennari, Konomi Noguchi, Shingo Sakamoto, Noriho Kawanami, Toshinori Mukae, Hiroshi Yatera, Kazuhiro |
author_facet | Tahara, Masahiro Oda, Keishi Yamasaki, Kei Kawaguchi, Takako Sennari, Konomi Noguchi, Shingo Sakamoto, Noriho Kawanami, Toshinori Mukae, Hiroshi Yatera, Kazuhiro |
author_sort | Tahara, Masahiro |
collection | PubMed |
description | BACKGROUND: Nintedanib is an inhibitor of receptor tyrosine kinases, including vascular endothelial growth factor receptor, but its effects on pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF) patients with chronic hypoxia were unclear. METHODS: This study included a nintedanib prospective study and historical control study. In the nintedanib prospective study, pulmonary artery systolic pressure (PASP) measured using transthoracic echocardiography was evaluated at six points during 48 weeks in 16 IPF patients in whom nintedanib was started. In the historical control study, adjusted annual change in PASP was compared between patients treated with (n = 16) and without (n = 15) nintedanib. RESULTS: In the nintedanib prospective study, the mean PASP at 48 weeks after starting nintedanib was significantly higher compared to that at baseline. When IPF patients were divided into two groups, IPF patients with or without long-term oxygen treatment (LTOT), mean PASP at 48 weeks was significantly higher than that at baseline only in IPF patients receiving LTOT (P = 0.001). In the historical control study, adjusted annual change in PASP in IPF patients treated with nintedanib was significantly lower than that in patients treated with no antifibrotic agents when considering patients without LTOT (0.26 mmHg vs 7.05 mmHg; P = 0.011). CONCLUSIONS: We found differential effects of nintedanib on PH between IPF patients with or without LTOT. Nintedanib may have a disadvantageous effect on PH in IPF patients with LTOT. Conversely, nintedanib treatment may be beneficial to PH in IPF patients without LTOT. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12890-019-0918-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6704493 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-67044932019-08-22 Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy Tahara, Masahiro Oda, Keishi Yamasaki, Kei Kawaguchi, Takako Sennari, Konomi Noguchi, Shingo Sakamoto, Noriho Kawanami, Toshinori Mukae, Hiroshi Yatera, Kazuhiro BMC Pulm Med Research Article BACKGROUND: Nintedanib is an inhibitor of receptor tyrosine kinases, including vascular endothelial growth factor receptor, but its effects on pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF) patients with chronic hypoxia were unclear. METHODS: This study included a nintedanib prospective study and historical control study. In the nintedanib prospective study, pulmonary artery systolic pressure (PASP) measured using transthoracic echocardiography was evaluated at six points during 48 weeks in 16 IPF patients in whom nintedanib was started. In the historical control study, adjusted annual change in PASP was compared between patients treated with (n = 16) and without (n = 15) nintedanib. RESULTS: In the nintedanib prospective study, the mean PASP at 48 weeks after starting nintedanib was significantly higher compared to that at baseline. When IPF patients were divided into two groups, IPF patients with or without long-term oxygen treatment (LTOT), mean PASP at 48 weeks was significantly higher than that at baseline only in IPF patients receiving LTOT (P = 0.001). In the historical control study, adjusted annual change in PASP in IPF patients treated with nintedanib was significantly lower than that in patients treated with no antifibrotic agents when considering patients without LTOT (0.26 mmHg vs 7.05 mmHg; P = 0.011). CONCLUSIONS: We found differential effects of nintedanib on PH between IPF patients with or without LTOT. Nintedanib may have a disadvantageous effect on PH in IPF patients with LTOT. Conversely, nintedanib treatment may be beneficial to PH in IPF patients without LTOT. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12890-019-0918-3) contains supplementary material, which is available to authorized users. BioMed Central 2019-08-22 /pmc/articles/PMC6704493/ /pubmed/31438928 http://dx.doi.org/10.1186/s12890-019-0918-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Tahara, Masahiro Oda, Keishi Yamasaki, Kei Kawaguchi, Takako Sennari, Konomi Noguchi, Shingo Sakamoto, Noriho Kawanami, Toshinori Mukae, Hiroshi Yatera, Kazuhiro Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy |
title | Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy |
title_full | Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy |
title_fullStr | Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy |
title_full_unstemmed | Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy |
title_short | Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy |
title_sort | temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704493/ https://www.ncbi.nlm.nih.gov/pubmed/31438928 http://dx.doi.org/10.1186/s12890-019-0918-3 |
work_keys_str_mv | AT taharamasahiro temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy AT odakeishi temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy AT yamasakikei temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy AT kawaguchitakako temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy AT sennarikonomi temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy AT noguchishingo temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy AT sakamotonoriho temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy AT kawanamitoshinori temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy AT mukaehiroshi temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy AT yaterakazuhiro temporalechocardiographicassessmentofpulmonaryhypertensioninidiopathicpulmonaryfibrosispatientstreatedwithnintedanibwithorwithoutoxygentherapy |